Former Scientist I at SPRI (7 years) - Recensione dipendente - Scientist I presso Merck

4,0
23 gen 2013
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

there were many opportunities to grow a very collaborative atmosphere lots of mentoring available variety as projects change exposure to outsourcing exposure to technology transfer

Svantaggi

not much to say really, as SPRI/SP no longer exists, but it could be long hours based on project or pilot plant needs, as well as travel.

Esplora altre recensioni su Merck

5,0
30 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Excellent company to work with.

Svantaggi

No cons encountered so far

4,0
30 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Svantaggi

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Vedi recensioni per: Utile|Valutazione|Data|Tutto